{"id":"64cu-sar-bispsma","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This agent combines a copper-64 radionuclide with a bisPSMA targeting ligand that selectively binds to PSMA, a cell-surface antigen highly expressed on prostate cancer cells. The radioactive copper-64 enables PET imaging to detect and localize PSMA-positive lesions, facilitating diagnostic imaging and treatment planning. The bisPSMA design provides enhanced binding affinity and specificity for improved tumor visualization.","oneSentence":"64Cu-SAR-bisPSMA is a copper-64 labeled radiopharmaceutical that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:07.825Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of PSMA-positive prostate cancer"},{"name":"Detection and localization of metastatic prostate cancer lesions"}]},"trialDetails":[{"nctId":"NCT06970847","phase":"PHASE3","title":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","status":"RECRUITING","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2025-05-16","conditions":"Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent","enrollment":220},{"nctId":"NCT06056830","phase":"PHASE3","title":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","status":"RECRUITING","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2023-12-21","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":383},{"nctId":"NCT04868604","phase":"PHASE1, PHASE2","title":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","status":"RECRUITING","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2021-08-11","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":54},{"nctId":"NCT06907641","phase":"PHASE2","title":"Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy","status":"RECRUITING","sponsor":"St Vincent's Hospital, Sydney","startDate":"2024-11-21","conditions":"Prostate Cancer (Post Prostatectomy)","enrollment":50},{"nctId":"NCT05249127","phase":"PHASE1, PHASE2","title":"64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)","status":"COMPLETED","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2022-04-11","conditions":"Biochemical Recurrence of Malignant Neoplasm of Prostate","enrollment":52},{"nctId":"NCT04839367","phase":"PHASE1","title":"Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)","status":"COMPLETED","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2021-07-13","conditions":"Prostatic Neoplasms","enrollment":30},{"nctId":"NCT05286840","phase":"PHASE1, PHASE2","title":"64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer","status":"UNKNOWN","sponsor":"Luke Nordquist, MD","startDate":"2022-03-28","conditions":"Prostate Cancer","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"64Cu-SAR-bisPSMA","genericName":"64Cu-SAR-bisPSMA","companyName":"Clarity Pharmaceuticals Ltd","companyId":"clarity-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"64Cu-SAR-bisPSMA is a copper-64 labeled radiopharmaceutical that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors. Used for PET imaging of PSMA-positive prostate cancer, Detection and localization of metastatic prostate cancer lesions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}